Shares of Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) have been given an average recommendation of “Hold” by the twelve brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $24.50.
Several research analysts have weighed in on the company. Robert W. Baird boosted their price target on Fortrea from $28.00 to $30.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. William Blair reissued a “market perform” rating on shares of Fortrea in a report on Friday, November 8th. TD Cowen boosted their target price on Fortrea from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Evercore ISI decreased their target price on Fortrea from $22.00 to $20.00 and set an “in-line” rating on the stock in a report on Tuesday, October 8th. Finally, Bank of America decreased their target price on Fortrea from $26.00 to $21.00 and set an “underperform” rating on the stock in a report on Tuesday, August 13th.
Get Our Latest Report on Fortrea
Institutional Trading of Fortrea
Fortrea Stock Up 4.2 %
NASDAQ:FTRE opened at $21.55 on Monday. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -6.05, a price-to-earnings-growth ratio of 3.15 and a beta of 0.70. Fortrea has a twelve month low of $16.53 and a twelve month high of $41.02. The stock’s 50 day moving average price is $19.48 and its two-hundred day moving average price is $22.63. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.74.
Fortrea (NASDAQ:FTRE – Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.02). The company had revenue of $674.90 million for the quarter, compared to analyst estimates of $674.86 million. Fortrea had a positive return on equity of 2.00% and a negative net margin of 10.99%. The firm’s revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period last year, the firm earned $0.24 EPS. Equities research analysts expect that Fortrea will post 0.57 earnings per share for the current fiscal year.
About Fortrea
Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Further Reading
- Five stocks we like better than Fortrea
- What Is WallStreetBets and What Stocks Are They Targeting?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Calculate Inflation Rate
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.